{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-069156","form_type":"8-K","ticker":"ANNX","cik":"0001528115","company_name":"Annexon, Inc.","filed_at":"2025-05-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.627230+00:00","generated_at":"2026-05-21T23:33:13.422375+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Annexon Q1 net loss $54.4M; cash $263.7M; GBS, GA programs advancing","bullets":["Net loss $54.4M ($0.37/share) vs $25.2M ($0.21/share) in Q1 2024; R&D expense $48.2M, up from $21.0M.","Cash and short-term investments $263.7M; runway into H2 2026.","FDA meeting for tanruprubart (ANX005) in GBS scheduled Q2 2025; open-label FORWARD study starting Q2 2025; BLA submission planned.","Phase 3 ARCHER II for ANX007 in dry AMD with GA enrollment completion expected Q3 2025; top line data H2 2026.","Proof-of-concept trial for oral C1s inhibitor ANX1502 in cold agglutinin disease anticipated completion mid-2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-069156","json":"https://secwatch.observer/filing/0000950170-25-069156.json","markdown":"https://secwatch.observer/filing/0000950170-25-069156.md","text":"https://secwatch.observer/filing/0000950170-25-069156.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1528115/000095017025069156/0000950170-25-069156-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1528115/000095017025069156/annx-20250512.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T23:33:13.422375+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}